CN1813916A - Compound chinese medicine formulation for treating common cold and its preparing process - Google Patents
Compound chinese medicine formulation for treating common cold and its preparing process Download PDFInfo
- Publication number
- CN1813916A CN1813916A CNA2005100956209A CN200510095620A CN1813916A CN 1813916 A CN1813916 A CN 1813916A CN A2005100956209 A CNA2005100956209 A CN A2005100956209A CN 200510095620 A CN200510095620 A CN 200510095620A CN 1813916 A CN1813916 A CN 1813916A
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- doubly
- group
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 89
- 238000000034 method Methods 0.000 title claims description 31
- 230000008569 process Effects 0.000 title claims description 7
- 201000009240 nasopharyngitis Diseases 0.000 title abstract description 3
- 239000000203 mixture Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 title description 2
- 238000009472 formulation Methods 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims abstract description 32
- 241000746375 Andrographis Species 0.000 claims abstract description 16
- 239000000463 material Substances 0.000 claims abstract description 11
- 241000233838 Commelina Species 0.000 claims abstract description 9
- 239000008187 granular material Substances 0.000 claims description 81
- 229940079593 drug Drugs 0.000 claims description 44
- 206010022000 influenza Diseases 0.000 claims description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000008517 radix Trichosanthis Substances 0.000 claims description 15
- 239000002552 dosage form Substances 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 238000005516 engineering process Methods 0.000 claims description 11
- 241000555712 Forsythia Species 0.000 claims description 8
- 235000014435 Mentha Nutrition 0.000 claims description 8
- 241001072983 Mentha Species 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 235000019634 flavors Nutrition 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 235000008504 concentrate Nutrition 0.000 claims description 6
- 238000004821 distillation Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 230000003068 static effect Effects 0.000 claims description 6
- 239000000341 volatile oil Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000555682 Forsythia x intermedia Species 0.000 abstract 1
- 244000246386 Mentha pulegium Species 0.000 abstract 1
- 235000016257 Mentha pulegium Nutrition 0.000 abstract 1
- 235000004357 Mentha x piperita Nutrition 0.000 abstract 1
- 241000218989 Trichosanthes Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 235000001050 hortel pimenta Nutrition 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 51
- 210000004072 lung Anatomy 0.000 description 48
- 241000699666 Mus <mouse, genus> Species 0.000 description 38
- 241000700605 Viruses Species 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 239000002609 medium Substances 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 201000010099 disease Diseases 0.000 description 16
- 241000712461 unidentified influenza virus Species 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 230000003203 everyday effect Effects 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- 239000013641 positive control Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 206010011224 Cough Diseases 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 230000036541 health Effects 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 229940100050 virazole Drugs 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 241000700199 Cavia porcellus Species 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 206010070834 Sensitisation Diseases 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 230000008313 sensitization Effects 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 5
- 208000015220 Febrile disease Diseases 0.000 description 5
- 208000008454 Hyperhidrosis Diseases 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 229920001525 carrageenan Polymers 0.000 description 5
- 235000010418 carrageenan Nutrition 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 5
- 230000000242 pagocytic effect Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 108010001062 polysaccharide-K Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 206010008531 Chills Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 229960001660 histamine phosphate Drugs 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 210000001331 nose Anatomy 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 206010063659 Aversion Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000013219 diaphoresis Diseases 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 235000010603 pastilles Nutrition 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000575 pesticide Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 238000003672 processing method Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 241001092500 Photinia x fraseri Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000607762 Shigella flexneri Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960003556 aminophylline Drugs 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 230000003067 hemagglutinative effect Effects 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 231100000668 minimum lethal dose Toxicity 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 210000005182 tip of the tongue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 208000031636 Body Temperature Changes Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 102000009338 Gastric Mucins Human genes 0.000 description 1
- 108010009066 Gastric Mucins Proteins 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 1
- 241000219470 Mirabilis Species 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000003851 azoles Chemical group 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000009916 yin-huang Substances 0.000 description 1
- 239000009792 yinqiao Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Group | Dosage (g/kg) | Incubation period (second) | Two minutes cough number of times |
Model contrast codeine doubly-linked cold granules | - 0.05 22.4 11.2 5.6 | 23.1±7.5 45.5±12.2** 43.9±6.7** 39.0±9.1* 26.8±8.8 | 66±17 37±9** 40±16** 49±10** 59±16 |
Group | Dosage (g/kg) | Draw and breathe heavily incubation period (second) |
Model contrast aminophylline doubly-linked cold granules | - 0.13 7.40 3.70 1.85 | 95.2±13.0 352.5±10.1** 147.0±22.9** 112.3±16.4* 100.4±18.7 |
Group | Dosage (g/kg) | Swelling rate (%) | |||||
1h | 2h | 3h | 4h | 5h | 6h | ||
Model contrast aspirin doubly-linked cold granules | 0.1 11.2 5.6 2.8 | 40.3± 15.5 16.4± 11.8** 13.0± 20.2** 19.7± 11.4* 39.5± 23.1 | 74.2± 51.1 18.5± 4.6** 18.5± 15.1** 24.3± 21.8* 69.9± 28.6 | 119.9 ±96.9 22.4± 11.7* 38.9± 23.9* 67.2± 20.3 75.4± 26.7 | 164.2 ±90.0 31.2± 13.7** 60.1± 25.9** 107.7 ±29.6 107.9 ±47.6 | 157.0± 82.9 56.4± 31.8** 79.9± 30.7* 109.2± 25.1 123.4± 26.7 | 149.9± 64.4 68.1± 41.0** 70.6± 32.5** 77.6± 32.4* 136.3± 35.4 |
Group | Dosage (g/kg) | The fervescence value (℃) | ||||||||
20 | 40 | 60 | 80 | 100 | 120 | 140 | 160 | 180 | ||
Model contrast aspirin doubly-linked cold granules | 0.1 11.2 5.6 2.8 | 0.85± 0.49 0.33± 0.20** 0.31± 0.21* 0.55± 0.34 0.48± 0.27 | 1.08± 0.35 0.28± 0.24** 0.26± 0.24* 0.73± 0.29 0.91± 0.36 | 1.51± 0.43 0.23± 0.16** 0.29± 0.14** 0.89± 0.40* 1.01± 0.32* | 1.37± 0.38 0.36± 0.15** 0.31± 0.22** 0.78± 0.33* 0.98± 0.29* | 1.33± 0.38 0.54± 0.22** 0.34± 0.19** 0.75± 0.25** 0.94± 0.25* | 1.19± 0.37 0.55± 0.27** 0.43± 0.20** 0.67± 0.36* 0.91± 0.40 | 1.08± 0.34 0.34± 0.17** 0.29± 0.21* 0.60± 0.33 0.88± 0.41 | 0.95± 0.33 0.25± 0.29** 0.29± 0.20* 0.66± 0.34 0.82± 0.45 | 0.95± 0.36 0.19± 0.26** 0.20± 0.22* 0.59± 0.35 0.66± 0.29 |
Group | Dosage (g/kg) | Clean up index K | Phagocytic index α |
Negative control group positive controls doubly-linked cold granules | 0.8 22.4 11.2 5.6 | 0.0297±0.011 0.0445±0.012** 0.0435±0.013** 0.0424±0.012* 0.0319±0.012 | 4.635±0.644 5.377± 0.607** 5.359± 0.581** 5.247±0.829 4.742±0.741 |
Group | Dosage (g/kg) | Swelling degree (mg) |
Sensitization group negative control group krestin doubly-linked cold granules not | 0.8 22.4 11.2 5.6 | 1.25±0.39** 4.28±0.51 6.23±0.71** 6.19±0.82** 5.36±0.54* 5.23±0.48* |
Group | Dosage (g/kg) | HC 50 |
Negative control krestin doubly-linked cold granules | 0.8 22.4 11.2 5.6 | 242.57±38.86 324.90±52.81** 301.36±40.96** 295.47±46.49* 268.37±48.19 |
Experimental group (n=12) | Dosage (the g crude drug/kg) | Mortality rate (%) | Dead protective rate (%) | Mean survival time (my god) | Prolong vital rates (%) |
The contrast of doubly-linked cold granules virazole model | 22.4 11.2 5.6 0.025 - | 16.7 41.7 83.3 16.7 100 | 83.3 58.3 16.7 83.3 | 11.5 10.6 9.3 13 7 | 64.3 51.4 32.9 85.7 |
Group | Dosage (the g crude drug/kg) | Lung index (meansigma methods) | Pneumonopathy range degree (meansigma methods) |
Doubly-linked cold granules virazole model control group normal control group | 22.4 11.2 5.6 0.025 - - | 1.32 1.27 1.65 1.15 1.80 0.81 | 0.74 1.43 2.07 0.81 2.90 0 |
Group | Dosage (the g crude drug/kg) | Virus titer (lgX) | Inhibition index |
Doubly-linked cold granules virazole papova matched group | 22.4 11.2 5.6 0.025 - | 0.98 1.81 2.20 0.60 5.79 | 4.81 3.98 3.59 5.19 |
Processing method | Time (hr) | Blood cell absorption (Hd) | Hemagglutinative titer (HA) |
Sample 2mg crude drug/ml anticipates cell sample 1mg crude drug/ml and anticipates cell sample 2mg crude drug/ml and add FM1 and put 4 ℃ and add cell biased sample 1mg crude drug/ml after spending the night and add FM1 and put 4 ℃ and add cell biased sample 2mg crude drug/ml after spending the night and add to add simultaneously behind the FM1 and add simultaneously the contrast of cell mixed model contrast control cells after cell biased sample 1mg crude drug/ml adds FM1 | 48 72 48 72 | - + - + - - - - ++ - - | 4 8 4 8 2 4 2 4 16 - - |
Strain | The strain number | The MIC scope | MIC50 | MIC90 |
The bloodthirsty hemophilus influenza Diplococcus pneumoniae of staphylococcus aureus e coli bacillus pyocyaneus shigella flexneri | 26 23 14 17 13 15 | 0.625-10 1.25-40 10->80 0.625-20 0.313-10 0.625-20 | 1.25 5 >80 1.25 1.25 2.5 | 10 40 >80 20 10 20 |
Group | Dosage (g/kg) | Log10 dose | Test mice number (only) | Dead mouse number (only) | Mortality rate (%) | Experiment probit | ED 50And 95% fiducial limit (g/kg) |
123456 model group | 16 11.2 7.84 5.49 3.84 2.69 - | 1.2 1.05 0.89 0.74 0.58 0.43 | 10 10 10 10 10 10 10 | 2 2 4 5 8 9 10 | 90 80 50 40 20 20 100 | 4.16 4.16 4.75 5 5.84 6.28 | 6.60 (5.29-8.24) |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100956209A CN100484545C (en) | 2005-11-25 | 2005-11-25 | Chinese medicine compound formulation for treating common cold and its preparing process |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100956209A CN100484545C (en) | 2005-11-25 | 2005-11-25 | Chinese medicine compound formulation for treating common cold and its preparing process |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1813916A true CN1813916A (en) | 2006-08-09 |
CN100484545C CN100484545C (en) | 2009-05-06 |
Family
ID=36906348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100956209A Active CN100484545C (en) | 2005-11-25 | 2005-11-25 | Chinese medicine compound formulation for treating common cold and its preparing process |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100484545C (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105012400A (en) * | 2015-08-10 | 2015-11-04 | 山东罗欣药业集团股份有限公司 | Soft traditional Chinese medicine composition capsules for treating cold and preparation method thereof |
CN105055528A (en) * | 2015-08-10 | 2015-11-18 | 山东罗欣药业集团股份有限公司 | Traditional Chinese medicine composition self-emulsifying soft capsule used for treating cold, and preparation method thereof |
-
2005
- 2005-11-25 CN CNB2005100956209A patent/CN100484545C/en active Active
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105012400A (en) * | 2015-08-10 | 2015-11-04 | 山东罗欣药业集团股份有限公司 | Soft traditional Chinese medicine composition capsules for treating cold and preparation method thereof |
CN105055528A (en) * | 2015-08-10 | 2015-11-18 | 山东罗欣药业集团股份有限公司 | Traditional Chinese medicine composition self-emulsifying soft capsule used for treating cold, and preparation method thereof |
CN105055528B (en) * | 2015-08-10 | 2019-02-15 | 山东罗欣药业集团股份有限公司 | A kind of Chinese medicine composition self-emulsifying soft capsule and preparation method thereof for treating flu |
CN105012400B (en) * | 2015-08-10 | 2019-02-15 | 山东罗欣药业集团股份有限公司 | A kind of Chinese traditional medicine composition composition soft capsule and preparation method thereof for treating flu |
Also Published As
Publication number | Publication date |
---|---|
CN100484545C (en) | 2009-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1207033C (en) | Traditional Chinese medicine composition for curing wind-heat type cold and its preparing method | |
CN1947754A (en) | Medicine for treating infantile asthma and its prepn. method | |
CN1772079A (en) | Medicine for treating upper respiratory tract infection and preparation method thereof | |
CN1682842A (en) | Chinese medicine composition for diminishing-inflammation and detoxication and its preparing method and use | |
CN103028001A (en) | Traditional Chinese medicine prescription for relieving asthma, relieving cough and resisting inflammatory, preparation method and application thereof | |
CN102526568B (en) | Traditional Chinese medicine compound composition | |
CN1813916A (en) | Compound chinese medicine formulation for treating common cold and its preparing process | |
CN1857362A (en) | Jingankang medicine preparation and its preparing process | |
CN1772136A (en) | Medicine composition for treating soft tissue damage and osteoarthropathy and its prepn process | |
CN1660343A (en) | Combination of medication of containing eucalyptol, limonene and alpha pinene and application | |
CN1245189C (en) | Composition for strengthening body resistance and restoring and function, strengthening spleen and kidney, relieving metal stress and promoting blood circulation to remove blood stasis | |
CN101053600A (en) | Medicinal composition for treating cough and preparation method and application thereof | |
CN1606979A (en) | Effect of scutellarein as antifebrile, analgesic, antiphlogistic, antibiotic and antiviral agent | |
CN1903254A (en) | Compound medicine for treating wind-heat type cold and preparing method thereof | |
CN1846761A (en) | Medicine for treating cold and cough and its prepn process | |
CN100337658C (en) | Chinese medicine composition for treating cold anemopyretic syndrome, and its preparing method | |
CN1056298C (en) | External use medicine for treating soft tissue injury and its producing method | |
CN1323681C (en) | Compound preparation for upper respiratory tract infection and its use in production of medicines | |
CN1899560A (en) | Compound preparation for treating summer wet type cold and its preparing method | |
CN1919270A (en) | Composition, exract, and pharmaceutical use thereof | |
CN1296088C (en) | Medicine for treating acute pharyngitis of children and preparation method thereof | |
CN1650903A (en) | Method of extracting roice clearing medicament from effective component in natural plant Chinese medicine | |
CN1282460C (en) | Chinese traditional medieine for treating cold and preparing technique | |
CN1742845A (en) | Medicine for treating rheumatism and rheumatoid diseases and preparing method | |
CN1634413A (en) | Bastard speedwell injection and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANDONG LUOXIN PHARMACY STOCK CO., LTD. Free format text: FORMER OWNER: CHINA PHARMACEUTICAL UNIVERSITY Effective date: 20140612 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Yunman Inventor after: Wang Chunyan Inventor after: Ni Zheng Inventor after: Wu Yulin Inventor after: Pu Cunhai Inventor after: Zhang Aihua Inventor after: Fang Weirong Inventor after: Gong Xiaojian Inventor after: Li Minghua Inventor after: Li Xiaofeng Inventor before: Li Yunman Inventor before: Ni Zheng Inventor before: Wu Yulin Inventor before: Pu Cunhai Inventor before: Zhang Aihua Inventor before: Fang Weirong Inventor before: Gong Xiaojian |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LI YUNMAN NI ZHENG WU YULIN PU CUNHAI ZHANG AIHUA FANG WEIRONG GONG XIAOJIAN TO: LI YUNMAN NI ZHENG WU YULIN PU CUNHAI ZHANG AIHUA FANG WEIRONG GONG XIAOJIAN LI MINGHUA LI XIAOFENG WANG CHUNYAN Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 276017 LINYI, SHANDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140612 Address after: Seven of 276017 Shandong city of Linyi province high tech Industrial Development Zone Patentee after: SHANDONG LUOXIN PHARMACY STOCK Co., LTD. Address before: Nanjing City, Jiangsu Province, Tong Lane 210009 No. 24 Patentee before: China Pharmaceutical University |
|
C56 | Change in the name or address of the patentee |
Owner name: SHANDONG LUOXIN PHARMACY GROUP CO., LTD. Free format text: FORMER NAME: SHANDONG LUOXIN PHARMACY STOCK CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: Seven of 276017 Shandong city of Linyi province high tech Industrial Development Zone Patentee after: Shandong Luo Xin Pharmaceutical Group Plc Address before: Seven of 276017 Shandong city of Linyi province high tech Industrial Development Zone Patentee before: SHANDONG LUOXIN PHARMACY STOCK Co., LTD. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210108 Address after: No.9 Tengfei Road, Yishui County, Linyi City, Shandong Province Patentee after: SHANDONG LUOXIN LEKANG PHARMACEUTICAL Co.,Ltd. Patentee after: SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK Co.,Ltd. Address before: Seven of 276017 Shandong city of Linyi province high tech Industrial Development Zone Patentee before: SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK Co.,Ltd. |